Bank of America Securities Reduces PT on Merck & Co., Inc. (MRK), Keeps a Buy Rating

​Merck & Co., Inc. (NYSE:MRK) is one of the Best Forever Stocks to Invest In Now. On October 10, Tim Anderson of Bank of America Securities reduced the firm’s price target on Merck & Co., Inc. (NYSE:MRK) from $99 to $98, while keeping a Buy rating on the stock.

​The firm sees the company as currently undervalued and with significant potential for growth. Anderson noted that the company faces some near-term challenges, including a decline in Gardasil sales and anticipated competition for its Keytruda. However, he sees significant gross prospects for Merck & Co., Inc. (NYSE:MRK) stemming from upcoming launches, including Winrevair.

​Anderson noted that the company is priced too low, considering its growth prospects. Moreover, he believes that the company’s slightly higher price-to-earnings multiple reflects investors’ confidence in its ability to deliver long-term.

​Merck & Co., Inc. (NYSE:MRK) is a global healthcare company that develops and sells prescription medicines, vaccines, and animal health products.

While we acknowledge the potential of MRK to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than MRK and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.